A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations-Reference-Cited by-同舟云学术

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

Published:2014-05-04 Issue:6 Volume:46 Page:595-600
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Kohsaka Shinji,Shukla Neerav,Ameur Nabahet,Ito Tatsuo,Ng Charlotte K Y,Wang Lu,Lim Diana,Marchetti Angela,Viale Agnes,Pirun Mono,Socci Nicholas D,Qin Li-Xuan,Sciot Raf,Bridge Julia,Singer Samuel,Meyers Paul,Wexler Leonard H,Barr Frederic G,Dogan Snjezana,Fletcher Jonathan A,Reis-Filho Jorge S,Ladanyi Marc

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.2969.pdf

Reference33 articles.

1. Malempati, S. & Hawkins, D.S. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr. Blood Cancer 59, 5–10 (2012).

2. Xia, S.J., Pressey, J.G. & Barr, F.G. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1, 97–104 (2002).

3. Breneman, J.C. et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21, 78–84 (2003).

4. Davis, R.J. et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54, 2869–2872 (1994).

5. Galili, N. et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5, 230–235 (1993).

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors;iScience;2024-10

2. Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers;2024-09-05

3. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma;Nature Communications;2024-07-26

4. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group;The Lancet Oncology;2024-07

5. Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy;Pediatric Blood & Cancer;2024-04-28